Procalcitonin as a Tool in Antibiotic Stewardship in Hospitals

How to Maximize Clinical and Economic Outcomes

Tuesday, August 6, 3:30 – 4:30 p.m.
Exhibit Hall, Theater 1
Supported by Thermo Fisher Scientific


When bacterial respiratory infection or sepsis are suspected, early intervention with appropriate antibiotic therapy is critical to outcomes. At the same time, reducing inappropriate use of antibiotics is important for minimizing the spread of antibiotic-resistant bacteria. Procalcitonin (PCT) is a biomarker that is playing an increasingly important role in helping clinicians identify patients with bacterial infections at risk for developing sepsis, severe sepsis and septic shock, and in helping manage their therapy. It is very important for hospitals to review the economic impact of improving testing turnaround times to determine when to start and stop antibiotic usage.


Attendees will:

  • Understand the regulation and kinetics of Procalcitonin during sepsis and infection and the concept of Procalcitonin-aided antibiotic stewardship in sepsis and low respiratory tract infections.
  • Compare and contrast the costs and outcomes with Procalcitonin-aided antibiotic therapy decisions compared to standard care in specific published patient population studies.
  • Summarize the most impactful cost components and value drivers of Procalcitonin testing.


Michael Broyles, PharmD
Director of Clinical Pharmacy and Laboratory Services
Five Rivers Medical Center
Pocahontas, AR